Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

Table 1

Baseline characteristics of patients.

Characteristics	All patients, (%)
Median age, years (IQR)	62 (56–69)
Sex, (%)
Male	41 (56.2)
Female	32 (43.8)
Histology, (%)
Mantle-cell lymphoma	17 (23.3)
Follicular lymphoma	20 (27.4)
Lymphocytic lymphoma (SLL/CLL)	11 (15.1)
Mucosa-associated lymphoid tissue	18 (24.7)
Other	7 (9.6)
Stage, (%)
I-II	13 (17.8)
III-IV	60 (82.2)
Prognostic groups for all patients (IPI), (%)
>2 risk factors	11 (15.1)
MIPI risk, (%)
Low (≤3)	4 (5.5)
Intermediate (4–5)	9 (12.3)
High (>5)	4 (5.5)
FLIPI risk, (%)
Low (≤1)	5 (6.8)
Intermediate (2)	3 (4.1)
High (3–5)	12 (16.4)
ECOG performance status
0~1	59 (80.8)
≥2	14 (19.2)
Number of previous treatments
1	33 (45.2)
≥2	40 (54.8)
Prior chemotherapy, (%)	37 (50.7)
Previous rituximab treatment, (%)	31 (42.5)
β2-MG (mg/L)	3.25 (2.28-4.89)

Abbreviations: IPI = International Prognostic Index; MIPI = mantle cell lymphoma IPI; FLIPI = follicular lymphoma IPI.